Table 7.

Short-acting bronchodilator use at the time of selected symptomatic respiratory adverse events

Parameter n (%)	Asthma stratum		COPD stratum
	Placebo N = 176	Regadenoson N = 356	Placebo N = 151	Regadenoson N = 316
Within 2 hours of study drug administration
Subjects who experienced a respiratory symptomatic adverse event of interesta	3 (1.7)	42 (11.8)	5 (3.3)	58 (18.4)
Subjects who used a short-acting bronchodilatorb	3 (1.7)	3 (0.8)	5 (3.3)	12 (3.8)
Subjects using a short-acting bronchodilator at time of selected adverse eventc	1 (0.6)	1 (0.3)	2 (1.3)	2 (0.6)
Within 24 hours of study drug administration
Subjects who experienced a respiratory symptomatic adverse event of interesta	4 (2.3)	46 (12.9)	6 (4.0)	60 (19.0)
Subjects who used a short-acting bronchodilatorb	94 (53.4)	168 (47.2)	65 (43.0)	141 (44.6)
Subjects using a short-acting bronchodilator at time of selected adverse eventc	2 (1.1)	5 (1.4)	2 (1.3)	5 (1.6)

COPD, chronic obstructive pulmonary disease.

^aDyspnea, wheezing, obstructive airways disorder, exertional dyspnea, and tachypnea (MedDRA version 11.1 preferred terms).

^bShort-acting bronchodilators defined as medications coded to drugs for obstructive airway diseases.

^cUse of a short-acting bronchodilator between the start and stop time of the specified respiratory adverse event of interest for each subject.